PubMed Health⌕ Search

Biomedical subjects

T Arika

Publications and source records attributed to T Arika.

14 recordsLinked to original sources
PubMed1992

Combination therapy of radiation and Sizofiran (SPG) on the tumor growth and metastasis on squamous-cell carcinoma NR-S1 in syngeneic C3H/He mice.

The efficacy of Sizofiran(SPG), a highly purified beta-1,3-D-glucan from the culture broth of basidiomycetes Schizophyllum commune Fries, in combination with local irradiation was investigated using squamous-cell carcinoma NR-S1 and syngeneic hosts of C3H/He mice. NR-S1 tumor was implanted sc in the thigh of C3H/He mice. When tumor grew to 4 mm in diameter, the local irradiation of 55 Gy was delivered. SPG was injected im at a dose of 5 mg/kg. When SPG was administered after irradiation, remarkable inhibition of tumor growth was observed in comparison with the radiation alone group. Furthermore, the combination effect of radiation and active immunotherapy using mitomycin C-treated NR-S1 cells as vaccine was examined. When radiotherapy and active immunotherapy were combined with SPG, suppression of tumor growth was observed from an early stage in comparison with the group which was not administered SPG. SPG also inhibited the pulmonary metastasis of NR-S1 tumor after radiotherapy.

Animals↗
PubMed1992

Topical treatment with butenafine significantly lowers relapse rate in an interdigital tinea pedis model in guinea pigs.

Butenafine is a novel antifungal agent of the class of benzylamines. The incidence of relapse after topical treatment with butenafine or bifonazole was investigated in a guinea pig interdigital tinea pedis model. One percent butenafine or bifonazole cream was applied on the infected site of animals for 20 consecutive days starting on day 10 postinfection. On day 30 posttreatment, relapse of the infection occurred in 11 of the 12 feet treated with bifonazole but in only 3 of the 12 feet treated with butenafine. The lower relapse rate after butenafine treatment might be attributable to its potent fungicidal activity and long retention time in the skin.

Administration, Topical↗
PubMed1991

[Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent].

In screening of new antifungal agents, bis(naphthalenemethyl)amines were found to have more potent antifungal activity than clotrimazole. Studies on their structure-activity relationships indicated that benzylamines had potent antifungal activity. Among them, butenafine hydrochloride (N-p-tert-butylbenzyl-N-methyl-1-naphthalenemethylamine hydrochloride, KP-363) has proved to show the strongest activity. It exhibits a wide spectrum activity in vitro against particularly dermatophytes (87 strains; minimal inhibitory concentration (MIC) range, 0.0015 to 0.05 microgram/ml), and also against Aspergillus (15 strains; MIC range, 0.025 to 0.78 microgram/ml), Cryptococcus neoformans (4 strains; MICs 0.78 and 1.56 micrograms/ml) and yeasts of genus Candida (67 strains; MIC range, 3.13 to greater than 100 micrograms/ml).

Animals↗
PubMed1990

Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental dermatophytosis in guinea pigs.

Butenafine hydrochloride, N-4-tert-butylbenzyl-N-methyl-1-naphthalenemethylamine hydrochloride (butenafine), is a novel antifungal agent of the class of benzylamine derivatives. Butenafine was investigated for its activity against guinea pig dermatophytosis caused by Trichophyton mentagrophytes or Microsporum canis in comparison with those of naftifine, tolnaftate, clotrimazole, and bifonazole. Topical butenafine showed excellent efficacy against dermatophytosis when it was applied once daily, and the effect was superior to those of all four reference drugs. When applied once at 24 or 48 h before infection, the drug exhibited excellent prophylactic efficacy against experimental T. mentagrophytes infection. The concentrations of butenafine in animal skin at 24 and 48 h after application of 0.2 ml of a 1% solution were several hundred times higher than those required to kill T. mentagrophytes and M. canis. The good efficacy of butenafine against dermatophytosis may be attributable to its fungicidal activity and long retention in the skin after topical application.

Animals↗
PubMed1990

Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental tinea pedis in guinea pigs.

Butenafine is a new antifungal benzylamine. The efficacy of butenafine was investigated in an experimental tinea pedis model in guinea pigs, which is pathologically similar to natural infections in humans. Butenafine (0.1 ml) in 0.2 to 1.0% solutions was applied to the site of infection. Treatment was started on day 10 postinfection and was continued for 20 days. Butenafine applied once daily exhibited excellent dose-related therapeutic efficacy. The efficacy of butenafine was significantly superior to those tolnaftate, clotrimazole, and bifonazole.

Animals↗
PubMed1988

Malignant ameloblastoma with pulmonary metastasis and hypercalcemia. Report of an autopsy case and review of the literature.

A case of malignant ameloblastoma with hypercalcemia in a 67-year-old Japanese woman is presented. The tumor of the maxilla was removed and diagnosed as a follicular ameloblastoma. The tumor recurred in the lower orbita-zygoma region, and multiple tumors of the lungs and hypercalcemia were detected eight months after the second operation. The recurrent tumor resembled the primary tumor but was less well differentiated. Autopsy revealed widespread lung metastasis of the malignant ameloblastoma, nephrocalcinosis, and sigmoid colon cancer. Histologic examination showed the metastatic ameloblastoma to be composed of nests and strands of basaloid and spindle-shaped cells surrounded by columnar cells arranged in palisade formation, with focal areas of squamous differentiation and occasional cystic degeneration. Only two cases of malignant ameloblastoma with hypercalcemia have previously been reported. This is the first case of malignant ameloblastoma with hypercalcemia and sigmoid colon cancer. In addition, prostaglandin E2 assay revealed that ameloblastoma produces prostaglandin E2, which results in hypercalcemia.

Aged↗
PubMed1986

[Combination therapy of radiation and schizophyllan (SPG) in C3H mouse squamous-cell carcinoma NR-S1].

The efficacy of schizophyllan, a beta-1, 3-D-glucan with a beta-1, 6-linked D-glucose residue isolated from Schizophyllum commune Fries, in combination with local radiation therapy was investigated using C3H mouse squamous-cell carcinoma NR-S1. Male C3H/He mice were implanted with 10(5) cells of NR-S1 tumor on day 0. On day 9 after implantation, mice received electron irradiation with a dose of 5,500 rads. Intramuscular injection of SPG (1.0 mg/kg and 5.0 mg/kg) was then started from the day following irradiation and repeated 15 times at one-day intervals. The antitumor effect was measured by the tumor size and survival time. Significant tumor growth suppression and prolongation of life-span were observed in the group given radiation and SPG (5.0 mg/kg) in comparison with the group which received radiation alone. In histopathological examination of irradiated tumor sites, stromal reactions accompanied by a much greater degree of cellular infiltration consisting of mainly lymphocytes were observed in the group given combined radiation and SPG (5.0 mg/kg).

Animals↗
PubMed1985

Purification, physicochemical characterization, and antitumor activity of a cancer-associated human serum protein that is increased by treatment with schizophyllan, an antitumor polysaccharide.

A serum protein was purified from normal human sera by several steps of purification, and tentatively designated as cancer-associated serum protein (CAP-135), since the content of the protein was remarkably decreased in cancer patients. The purified CAP-135 has an approximate molecular weight of 135,000 daltons, and is composed of three subunits of 78,000, 34,500 and 24,800 daltons. CAP-135 showed an isoelectric point of pH 5.5-5.8 and contained a small amount (1.38%) of neutral sugar. CAP-135 is assumed to be modified complement C3 on the basis that it reacted only with anticomplement C3 in immunodiffusion assay, and one of its subunits had a molecular weight similar to that of the beta-chain of human complement C3. The ip injection of CAP-135 apparently inhibited the growth of sarcoma-180 implanted into the groin of Jc1:ICR female mice. The present results indicate that CAP-135 may be of diagnostic value.

Amino Acids↗
PubMed1984

Special toxicology--physical dependence potential, antigenicity and mutagenicity--of mabuterol.

The physical dependence potency of dl-1- (4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-tert.-butyl-amino-ethanol hydrochloride (mabuterol) was tested in male rats dosed with 20, 100 and weekly increasing doses of 20, 40, 60, 80 and 100 mg/kg over 7 weeks. The results were compared with those after the same increasing dosages of morphine. 10 males were used per group. The effects of the antagonist levallorphan on drug dependency were also studied. No withdrawal signs were observed in any mabuterol-treated groups. No antigenic potency of mabuterol was found in a series of studies on guinea pigs and rats. In a series of mutagenicity studies (Ames-test, DNA repair test and micronucleus test) it could be demonstrated that mabuterol is not a mutagen.

Adrenergic beta-Agonists↗
PubMed1984

[Antitumor activity of schizophyllan (SPG) against syngeneic ACI/N rat tumor, AMC-60 fibrosarcoma and BC-47 bladder cancer].

The antitumor activity of schizophyllan (SPG) against syngeneic ACI/N rat tumor, AMC-60 fibrosarcoma and BC-47 bladder cancer was investigated. Intramuscular injection of SPG caused a marked suppression of AMC-60 tumor growth. Results obtained with cytotoxicity tests in vitro and lymphoblastogeneic response in vitro suggest the association of enhanced macrophage cytostasis and high reactivity of lymphoid cells with the resistance of the host to AMC-60 tumor. Moreover, SPG showed pronounced antitumor activity against BC-47 bladder cancer. The highest therapeutic effectiveness was obtained when SPG injection was started at an advanced stage of the tumor, 4 out of 15 rats treated being completely cured of cancer. Cytotoxicity tests in vitro and neutralization tests in vivo indicated the important role of cytotoxic lymphocytes as well as activated macrophages in the host defence mechanism against BC-47 cancer. This, taken together with the fact that the rats cured completely by SPG therapy acquired transplantation resistance to BC-47 cancer, shows that SPG may promote tumor immunity in the host.

Animals↗
PubMed1982

Cooperative role of T lymphocytes and macrophages in anti-tumor activity of mice pretreated with schizophyllan (SPG).

Anti-tumor activity was studied in mice injected with Schizophyllan (SPG), a glucan produced by Schizophyllum commune Fries. SPG-injected mice rejected subcutaneously inoculated sarcoma-180 and the anti-tumor activity was shown to be mediated by host spleen and lymph node cells. The anti-tumor activity lasted as long as 60 days after the SPG administration as assessed by transfer of cells into normal recipients. Cells involved in anti-tumor activity were shown to be T lymphocytes since anti-tumor activity was diminished when lymph node cells from SPG-treated mice were treated with anti-Thy-1.2 sera plus complement, whereas cells passed through a nylon wool column retained the activity. Macrophages were also shown to be involved since administration of carrageenan or trypan blue into the host decreased the inhibition ratio of tumor growth. It was concluded that anti-tumor activity in SPG-treated mice was mediated by the cooperation of T lymphocytes and macrophages, thus the impairment of either function decreased anti-tumor activity.

Animals↗
PubMed1982

[Experimental study on immunochemotherapy using schizophyllan].

Immunochemotherapy with schizophyllan (SPG) combined with chemotherapeutic agents was evaluated in two syngeneic tumor-C3H/He mouse systems. The administration of SPG alone caused a significant growth inhibition of MM 46 mammary carcinoma, the highest therapeutic effect being obtained by SPG given at the advanced stage of tumors. When combined with neocarzinostatin given 7-times every other day the simultaneous administration of SPG produced an optimal response to that therapy. In X-5563 plasmacytoma, SPG alone was ineffective. However, when combined with mitomycin C given with 1 to 5-days interval, the concurrent administration of SPG prolonged significantly the life-span of the tumor-bearing mice. These results indicated that the simultaneous administration of SPG and antitumor drugs may be a useful application method for immunochemotherapy of experimental tumors.

Adjuvants, Immunologic↗